189 related articles for article (PubMed ID: 9649135)
21. Neuron-specific enolase and S 100B protein as predictors of outcome in ischaemic stroke.
Kaca-Oryńska M; Tomasiuk R; Friedman A
Neurol Neurochir Pol; 2010; 44(5):459-63. PubMed ID: 21082487
[TBL] [Abstract][Full Text] [Related]
22. S-100b, sE-selectin, and sP-selectin for evaluation of hypoxic brain damage in patients after cardiopulmonary resuscitation: pilot study.
Mussack T; Biberthaler P; Kanz KG; Wiedemann E; Gippner-Steppert C; Jochum M
World J Surg; 2001 May; 25(5):539-43; discussion 544. PubMed ID: 11369976
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of S-100B protein and neuron specific-enolase as markers of traumatic brain damage in clinical use.
Naeimi ZS; Weinhofer A; Sarahrudi K; Heinz T; Vécsei V
Brain Inj; 2006 May; 20(5):463-8. PubMed ID: 16716992
[TBL] [Abstract][Full Text] [Related]
24. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?
Schlagenhauff B; Schittek B; Ellwanger U; Stroebel W; Blum A; Schwarz M; Rassner G; Garbe C
Melanoma Res; 2000 Oct; 10(5):451-9. PubMed ID: 11095406
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of multiple serum markers in advanced melanoma.
Díaz-Lagares A; Alegre E; Arroyo A; González-Cao M; Zudaire ME; Viteri S; Martín-Algarra S; González A
Tumour Biol; 2011 Dec; 32(6):1155-61. PubMed ID: 21858537
[TBL] [Abstract][Full Text] [Related]
26. S-100B and neuron specific enolase in outcome prediction of severe head injury.
Li N; Shen JK; Zhao WG; Cai Y; Li YF; Zhan SK
Chin J Traumatol; 2004 Jun; 7(3):156-8. PubMed ID: 15294113
[TBL] [Abstract][Full Text] [Related]
27. Protein S-100b serum levels in trauma-induced brain death.
Dimopoulou I; Korfias S; Dafni U; Anthi A; Psachoulia C; Jullien G; Sakas DE; Roussos C
Neurology; 2003 Mar; 60(6):947-51. PubMed ID: 12654958
[TBL] [Abstract][Full Text] [Related]
28. Comparison of four different assays for determination of serum S-100B.
Smit LH; Korse CM; Bonfrer JM
Int J Biol Markers; 2005; 20(1):34-42. PubMed ID: 15832771
[TBL] [Abstract][Full Text] [Related]
29. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up.
Aukema TS; Olmos RA; Korse CM; Kroon BB; Wouters MW; Vogel WV; Bonfrer JM; Nieweg OE
Ann Surg Oncol; 2010 Jun; 17(6):1657-61. PubMed ID: 20151211
[TBL] [Abstract][Full Text] [Related]
30. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B.
Strobel K; Skalsky J; Kalff V; Baumann K; Seifert B; Joller-Jemelka H; Dummer R; Steinert HC
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1366-75. PubMed ID: 17390135
[TBL] [Abstract][Full Text] [Related]
31. Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma.
Smit LH; Nieweg OE; Mooi WJ; Bonfrer JM; Haanen JB; Kroon BB; De Gast GC
Anticancer Res; 2008; 28(4C):2297-302. PubMed ID: 18751409
[TBL] [Abstract][Full Text] [Related]
32. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ
Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214
[TBL] [Abstract][Full Text] [Related]
33. S-100B concentrations predict disease-free survival in stage III melanoma patients.
Kruijff S; Bastiaannet E; Kobold AC; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2009 Dec; 16(12):3455-62. PubMed ID: 19636631
[TBL] [Abstract][Full Text] [Related]
34. Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100beta or melanoma inhibitory activity (MIA)?
Deichmann M; Benner A; Kuner N; Wacker J; Waldmann V; Näher H
Melanoma Res; 2001 Jun; 11(3):291-6. PubMed ID: 11468518
[TBL] [Abstract][Full Text] [Related]
35. A comparison of two different assays for determining S-100B in serum and urine.
Hallén M; Carlhed R; Karlsson M; Hallgren T; Bergenheim M
Clin Chem Lab Med; 2008; 46(7):1025-9. PubMed ID: 18624623
[TBL] [Abstract][Full Text] [Related]
36. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma.
Schultz ES; Diepgen TL; Von Den Driesch P
Br J Dermatol; 1998 Mar; 138(3):426-30. PubMed ID: 9580794
[TBL] [Abstract][Full Text] [Related]
37. Significance of serum S-100B in melanoma patients before and after sentinel node biopsy.
Smit LH; Nieweg OE; Korse CM; Bonfrer JM; Kroon BB
J Surg Oncol; 2005 May; 90(2):66-9; discussion 69-70. PubMed ID: 15844182
[TBL] [Abstract][Full Text] [Related]
38. S-100b and neuron-specific enolase in patients with fulminant hepatic failure.
Strauss GI; Christiansen M; Møller K; Clemmesen JO; Larsen FS; Knudsen GM
Liver Transpl; 2001 Nov; 7(11):964-70. PubMed ID: 11699032
[TBL] [Abstract][Full Text] [Related]
39. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.
Schmitz C; Brenner W; Henze E; Christophers E; Hauschild A
Anticancer Res; 2000; 20(6D):5059-63. PubMed ID: 11326668
[TBL] [Abstract][Full Text] [Related]
40. Elevated serum S-100B levels in children with temporal lobe epilepsy.
Calik M; Abuhandan M; Sonmezler A; Kandemır H; Oz I; Taskin A; Selek S; Iscan A
Seizure; 2013 Mar; 22(2):99-102. PubMed ID: 23146618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
